CervoMed Inc. announced completion of a Phase 1 healthy volunteer study evaluating the pharmacokinetics of a drug product containing a new, stable crystal form of neflamapimod and selected a 50 mg three-times-daily dosing regimen for its planned Phase 3 trial in patients with dementia with Lewy bodies. The company said the higher dose is intended to achieve plasma drug concentrations associated with therapeutic activity observed previously with a clinically active drug product batch used in the extension phase of the Phase 2b RewinD-LB trial. CervoMed stated that additional results and comparative pharmacokinetic data are being made available in its corporate presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603040730PRIMZONEFULLFEED9665479) on March 04, 2026, and is solely responsible for the information contained therein.